🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Read about the new appointments at Seamless Therapeutics #career #portfoliocompany #lifesciences #bitoech forbion.com/en/news/seamle…

Read more about the latest announcement from our portfolio company Synox forbion.com/en/news/synox_… #portfolionews #lifesciences #bitoech

Our 5th exit in just about a year. Congratulations team Forbion! forbion.com/en/news/forbio… #lifesciences #biotech Endpoints News #oncology

News from our portfolio company Pheon Therapeutics forbion.com/en/news/pheon_… #lifesciences #portfoliocompanynews #seriesB #financing

We are proud to announce our newest investment in Progentos Therapeutics. Forbion led the $65M series A round with General Partner Dmitrij Hristodorov and Sr Assoc Marc-Olivier Turgeon joining Progentos' board. forbion.com/en/news/forbio… #biotech

Read more about our participation in the $555m financing of Bicycle Therapeutics. forbion.com/en/news/bicycl… #financing #lifesciences #biotech #venturecapital #impactonpatients

Proud to announce the $1.25 Billion Sale to Johnson & Johnson of our portfolio company Numab Therapeutics Subsidiary. forbion.com/en/news/forbio… #lifesciences #biotech #biotechnology

Episode 4 of The Biotech Pulse is out now. If you want to learn more about the role of biotech as a discovery engine for pharma in research and development, then this is the episode for you. forbion.com/en/insights/th… #biotech #lifesciences #venturecapital #CEO #CTO

News from the Forbion Ventures Fund. Read more about our investment in Marea Tx. #biotech #lifesciences #cardionmetabolic forbion.com/en/news/forbio…

Excited to announce the first close of Forbion BioEconomy Fund I at €75M! This new fund invests in biotech solutions for Food, Agriculture, Materials, and Environmental Tech. #VentureCapital #Biotech #Sustainability #Forbion #BioEconomy forbion.com/en/news/forbio…

Join us in welcoming Josh Brumm, our newest General Partner! forbion.com/en/news/forbio… #appointment #lifesciences #biotech

Exclusive: Forbion, a European venture capital firm that manages around $3 billion, has recruited former Dyne Therapeutics CEO Josh Brumm as it expands into the U.S. trib.al/jGBlXbR

Just in: Forbion leads $170 M Series B Funding in Beacon Therapeutics forbion.com/en/news/forbio… #seriesB #financing #lifesciences #biotech #forbion

Catch up on the news of the series D financing of our portfolio company Catalym. forbion.com/en/news/forbio… #seriesD #lifesciences #biotech

Read more about our latest financing in AIRNA forbion.com/en/news/forbio… #seriesA #lead #RNA #Forbion

Read more about our latest investment in Navigator Medicines forbion.com/en/news/forbio… #lifesciences #financing #seriesA #forbion

Our second investment announcement from the Forbion BioEconomy Fund in 2 days. Welcome Novameat! Read more here: forbion.com/en/news/forbio… #lifesciences #bioeconomy #biotech #VC

Read more about our latest investment in LoQus23 Therapeutics forbion.com/en/news/forbio… #financing #biotech #lifesciences #SeriesA

Forbion proudly backs Purespring Therapeutics. Read more about this latest series B financing: forbion.com/en/news/puresp… #seriesB #lifesciences #biotech #financing

We are thrilled to announce our latest fundraise of over €2 Billion across two new funds! Check out the details: forbion.com/en/news/forbio… #LifeSciences #VentureCapital #Forbion #biotech